1. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Issue 2 (February 2020) Authors: Owen, Roger G; McCarthy, Helen; Rule, Simon; D'Sa, Shirley; Thomas, Sheeba K; Tournilhac, Olivier; Forconi, Francesco; Kersten, Marie José; Zinzani, Pier Luigi; Iyengar, Sunil; Kothari, Jaimal; Minnema, Monique C; Kastritis, Efstathios; Aurran-Schleinitz, Thérèse; Cheson, Bruce D; Walter, Harriet... Journal: Lancet Issue: Volume 7:Issue 2(2020) Page Start: e112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Advances in the treatment of follicular lymphoma. (February 2015) Authors: Ujjani, Chaitra; Cheson, Bruce D Journal: Expert opinion on orphan drugs Issue: Volume 3:Number 2(2015:Feb.) Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin''s lymphoma. Issue 9 (September 2010) Authors: Ujjani, Chaitra; Cheson, Bruce D Journal: Expert review of anticancer therapy Issue: Volume 10:Issue 9(2010) Page Start: 1353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bendamustine in the treatment of chronic lymphocytic leukemia. (June 2014) Authors: Ujjani, Chaitra; Cheson, Bruce D Journal: Expert opinion on orphan drugs Issue: Volume 2:Number 6(2014:Jun.) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bendamustine in the treatment of chronic lymphocytic leukemia. (June 2014) Authors: Ujjani, Chaitra; Cheson, Bruce D Journal: Expert opinion on orphan drugs Issue: Volume 2:Number 6(2014:Jun.) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin''s lymphoma. (April 2012) Authors: Koprivnikar, Jamie L; Cheson, Bruce D Journal: Future oncology Issue: Volume 8:Number 4(2012) Page Start: 359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Issue 11 (November 2020) Authors: Cheson, Bruce D; Bartlett, Nancy L; LaPlant, Betsy; Lee, Hun J; Advani, Ranjana J; Christian, Beth; Diefenbach, Catherine S; Feldman, Tatyana A; Ansell, Stephen M Journal: Lancet Issue: Volume 7:Issue 11(2020) Page Start: e808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Issue 8 (August 2016) Authors: Sehn, Laurie H; Chua, Neil; Mayer, Jiri; Dueck, Gregg; Trněný, Marek; Bouabdallah, Kamal; Fowler, Nathan; Delwail, Vincent; Press, Oliver; Salles, Gilles; Gribben, John; Lennard, Anne; Lugtenburg, Pieternella J; Dimier, Natalie; Wassner-Fritsch, Elisabeth; Fingerle-Rowson, Günter; Cheson, Bruce D Journal: Lancet oncology Issue: Volume 17:Issue 8(2016:Aug.) Page Start: 1081 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Issue 5 (May 2019) Authors: Morschhauser, Franck; Flinn, Ian W; Advani, Ranjana; Sehn, Laurie H; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W; Salles, Gilles; Tilly, Hervé; Chen, Andy I; Assouline, Sarit; Cheson, Bruce D; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan;... Journal: Lancet Issue: Volume 6:Issue 5(2019) Page Start: e254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab. (7th November 2013) Authors: Forero, Andres; Hamadani, Mehdi; Kipps, Thomas; Fanale, Michelle; Cuneo, Antonio; Perez de Oteyza, Jaime; Gladstone, Douglas; Andre, Marc; Bellam, Naresh; Goswami, Trishna; Ibrahim, Ramy; Schneider, Amy; Liang, Meina; Eck, Steven; Elgeioushi, Nairouz; Herbst, Ronald; Cheson, Bruce D Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗